Telomir Pharmaceuticals, Inc. TELO
1.23
0.02
1.65%
as of 25 Sep
- Market cap
- $83.2M
- P/E
- 0.0×
Follow TELO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
17.51 | 5.14 | 7.00 | 16.14 |
Net Debt/EBITDA |
6.39 | 3.41 | 5.15 | 2.85 | |
Debt/Assets |
0.00% | 0.00% | 3.50% | 2.54% | |
Debt/Equity |
0.00 | 0.00 | 0.04 | 0.03 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.84 | 0.58 | 1.79 | 0.02 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.03) | (0.04) | (0.05) | (0.02) | |
Cash per Share |
0.23 | 0.23 | 0.16 | 0.09 | |
Shareholders Equity per Share |
0.22 | 0.19 | 0.14 | 0.08 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.22 | 0.19 | 0.14 | 0.08 | |
Free Cash Flow |
(0.93) | (1.20) | (1.77) | (1.01) | |
Working Capital |
6.98 | 5.91 | 4.96 | 5.03 | |
Net Current Asset Value |
6.98 | 5.91 | 4.96 | 5.03 | |
| Other line items | |||||
Quick Ratio |
17.34 | 5.10 | 6.72 | 15.55 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.03) | (0.04) | (0.05) | (0.02) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
0.42 | 0.56 | 0.42 | 0.23 | |
Average Assets |
4.22 | 4.33 | 3.14 | 3.10 | |
Average Common Equity |
3.71 | 3.28 | 2.40 | 2.76 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates